3 Big FDA Updates Employers Should Know 🚨

We’re keeping a close eye on newly approved specialty drugs that could impact your plan costs and employee care strategies. Here are three important FDA updates from this month:

🔍Key FDA Approvals This Month

🧬Tremfya (guselkumab)

Approved for moderate to severe Crohn’s disease – now the first IL-23 inhibitor offering both IV and subcutaneous options.

🩸 Qfitlia (fitusiran)

Approved for hemophilia A and B – offering extended bleeding protection with a new antithrombin-based approach.

🛡️ Opdivo + Yervoy (nivolumab + ipilimumab)

Now fully approved as a first-line treatment for unresectable or metastatic liver cancer, showing improved survival rates.

📈Why It Matters for Employers

New specialty drug approvals create both opportunities and challenges for self-funded employers:

• Innovative therapies improve patient outcomes
• High costs can strain pharmacy budgets without the right strategies

At Dart-Care, we help you secure timely access to breakthrough therapies while managing overall drug spend through proven specialty cost management solutions.

Contact info@dart-care.com